Trump and pharma execs to discuss progress on COVID-19 cure
The White House task force and the US President will meet drug makers this afternoon to discuss "progress on a vaccine and cure".
In an early morning Tweet, US President Trump said he will be meeting with major pharmaceutical companies today at the White House to discuss "progress on a vaccine and cure" for coronavirus (COVID-19) outbreak. This statement comes after the infection claimed the country's second victim during the weekend.
Although Trump provided no further information or details, including clues as to which companies would be attending, it has been reported that executives from Sanofi, Johnson & Johnson, GSK and Pfizer will be appearing at this afternoon's meeting.
The head of the infectious diseases unit at the US National Institutes of Health, Dr Anthony Fauci, said he was concerned the number of US cases could jump in the coming weeks.
“When you have a number of cases that you’ve identified and they’ve been in the community for a while, you’re going to wind up seeing a lot more cases than you would have predicted,” he told CNN in an interview on Monday. He continued to explain his concern that "we’re going to see a lot more community-related cases" during the next few weeks.
Meanwhile, on the other side of the Atlantic, Prime Minister Boris Johnson, has said the spread of coronavirus is a "problem that is likely to become more significant".
Johnson's comment comes as the number of cases in the UK rises to 40. The prime minister has also chaired a meeting today of the government's emergency committee, Cobra, to agree a plan to tackle the crisis.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...